Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Controlled Trial of an Injectable Biologic and U0279 [acitretin] as Combination Therapy for Severe Plaque-Type Psoriasis.

Next Previous
X
Search
Trial Profile

Randomized, Controlled Trial of an Injectable Biologic and U0279 [acitretin] as Combination Therapy for Severe Plaque-Type Psoriasis.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 05 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Acitretin (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Stiefel Laboratories

    • Most Recent Events

    • 23 Jun 2011 Actual initiation date changed from Feb 2009 to Oct 2009, GlaxoSmithKline added in the association as reported by ClinicalTrials.gov.
    • 23 Apr 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 24 Feb 2010 Planned end date changed from 1 Dec 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top